Volume 10, Abstract Book BHS, February 2019

Index

ABSTRACTS

P59 Two cases of digestive vasculo-invasive candidiasis in patients with hematological disease


PP03 HLA typing with 11-loci-NGS: benefits in donor selection


PP02 Donor specific anti-HLA antibodies and allogeneic hematopoietic stem cell transplantation


PP01 CRISPR/Cas9 mediated gene correction for the Wiskott-Aldrich syndrome


P67 Analytical interference by dabigatran on Fibrinogen-C XL reagens resulting in spuriously low fibrinogen levels


P66 Adult itp patients treated with romiplostim in daily clinical practice: single center experience


P65 Hospital-acquired thrombocytopenia


P64 Interest of combination of two assays in diagnosis and follow-up of haemophilia A


P63 Tantalum bioactive glasses for hemostasis


P60 Monitoring of wHLA-DR expression in septic patients: feasibility and reproducibility study


PP04 Comparison of bone marrow and umbilical cord derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host-disease


P58 A multidisciplinary approach to diagnose X-linked HIGM CD40 ligand deficiency: a case report


P57 Characterization of regulatory T cell (Treg) subsets after allogeneic hematopoietic cell transplantation


P55 Neonatal haemolytic anaemia: a case of common hereditary elliptocytosis


P54 A case of auto-immune haemolytic anemia caused by pembrolizumab and complicated by transient bone marrow aplasia


P53 Phase III clinical trials with amustaline/glutathione (S-303/GSH) pathogen-inactivated RBC


P52 Multicenter evaluation of serologic rbc phenotyping by MDMulticard® (griffols) in patients receiving daratumumab


P51 Contribution of ngs in the diagnosis of Hereditary spherocytosis: case report


P48 Extreme thrombocytosis under azacitidine in a patient with secondary high-risk myelodysplastic syndrome: a case report


PP34 Chromosomal aberrations in chronic myeloid leukemia: response to conventional tyrosine kinase inhibitors and risk of blastic transformation


PP62 Treatment-free remission after TPO receptor agonists in adult itp patients in belgium


PP61 A randomized, double-blind, placebo-controlled, phase 3 study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura


PP56 Infectious complications of a novel tyrosine kinase inhibitor (ibrutinib) and correlation with immunological markers in patients with malignant hemopathies


PP50 Non-invasive fetal genotyping of RHCE C/c and E alleles in allo-immunized pregnant women: evaluation of a 7-year experience


PP49 Ravulizumab* (ALXN1210) vs eculizumab in complement inhibitor-naive adult patients with PNH


PP37 In vitro investigations of the effect of BCR-ABL tyrosine kinase inhibitors on endothelial cell viability


PP36 In vitro generation of tumor antigen-specific T-cells from healthy donor and patient stem cells


PP35 Efficacy and safety of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in real-world clinical practice: data from a Belgian registry


P47 Blastic plasmacytoid dendritic cell neoplasm: an uncommon CD4±CD5+CD10±CD303-presentation


PP33 miR-15a-5p and miR-21-5p contribute to chemoresistance in acute myeloid leukemia by targeting PDCD4, ARL2 and BTG2


PP17 Targeting of the histone methyltransferases G9a and GLP in multiple myeloma


PP16 Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder


PP15 Development of reticulocytosis through inhibition of terminal erythroid maturation by carfilzomib treatment in multiple myeloma


PP14 MRD analysis by next-generation sequencing in multiple myeloma and pediatric acute lymphoblastic leukemia


PP13 Targeting Protein Arginine Methyltransferase PRMT5 in high-risk multiple myeloma: a new treatment strategy?


PP12 Cognitive impairment, hypoalbuminemia, high CRP level and past history of gastro-intestinal ulcer: 4 markers of frailty which identify older patients with malignant hemopathies who don’t benefit from chemotherapy


PP05 Immune cytopenias after allogeneic hematopoietic stem cell transplantation in children


P09 Stronger impact of centre type compared to activity volume and quality management on the performance of autologous haematopoietic stem cell transplants in adults: report of the belgian transplant registry


P23 Amitryptilin strengthens effects of bortezomib and melphalan treatment in multiple myeloma by inhibiting acid sphingomyelinase


P22 Validation of a single 10-colours tube facilitating discrimination of monoclonal from polyclonal plasma cells in indolent myeloma


P21 Acute hepatitis after chlorambucil alone for chronic lymphocytic leukaemia (CLL)


P20 Contribution of next-generation sequencing analysis to the differential diagnosis of cutaneous lesions suspected of lymphoma


P19 Receptor tyrosine kinase AXL: a potential new target in multiple myeloma


P18 Ibrutinib, the first available BTK inhibitor: single centre experience


P11 Sporadic late-onset nemaline myopathy after allogeneic stem cell transplantation for refractory hepatosplenic gammadelta lymphoma: a case report


P10 Daratumumab administration: good nursing practices


P24 MRD discrepancy during follow-up of p190 BCR-ABL1+ childhood B-ALL: diagnosis of a ‘CML-like’ all subgroup


P08 Neutropenic fever complicating autologous stem cell transplantation in a general hospital: epidemiology and predisposing factors


P07 Immuno-T, 1 year into the motion comic: where we stand, and where we’re heading


P06 Predictive factors and timing of peripheral blood stem cell collection for autologous stem cell transplantation, Leuven, Belgium 2010–2014


06 Erythropoietin modulates red blood cells elimination


05 Overexpression of miR-15a-5p confers chemoresistance by inhibiting autophagy induced by daunorubicin in acute myeloid leukemia cell lines


04 Clofarabine-based consolidation improves relapse-free survival of patients with acute myeloid leukaemia with complex or micro-complex karyotype: results from the randomised alfa-0702 study


03 Renal allograft function following treatment of post-transplant lymphoproliferative disorder

F. Gelders, A. Laenen, A.A. Herelixka, B. Sprangers, D. Dierickx


02 Unravelling the landscape of copy number aberrations in Hodgkin Lymphoma: a joint KU Leuven and Lysa study on circulating cell-free dna

J. Finalet Ferreiro, T. Tousseyn, O. Gheysens, G. Verhoef, M. André, P. Vandenberghe, L. Buedts, L.M. Fornecker, J. Lazarovici, R. Casasnovas, C. Copie, L. Marcelis


P38 Donor and recipient developing JAK2 V617F positive myeloproliferative disease after stem cell transplantation: a case report


P46 Successful treatment with arsenic trioxide and retinoic acid for acute promyelocytic leukaemia in a very elderly patient: a case report


P45 A case report of acute panmyelosis with myelofibosis (APMF) with a distinct molecular pattern


P44 Current routine and beliefs in management of hyperleukocytic acute myeloid leukaemia in multiple belgian centres based on an electronic survey


P43 Contribution of the structural parameters of Sysmex-XN9000 haematology analyser to the differential diagnosis of monocytosis and lymphocytosis in routine laboratory practice


P42 The spectrum of related malignancies


P41 Impact of stopping tyrosine kinase inhibitor therapy on the molecular workload for monitoring: a single centre experience


P40 FIP1L1-PDGFRA P.T674I-D842L: a novel and ponatinib resistant compound mutation in FIP1L1-PDGFRA positive eosinophilic leukaemia


P39 Mutational landscape of 109 MDS and 64 AML patients: a single-centre study


01 A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stromal cells after myeloablative or non-myeloablative conditioning in patients with haematological malignancies

A. De Becker, R. Schots, T. Kerre, D. Mazure, J. Maertens, E. Baudoux, C. Lechanteur, Y. Beguin


P32 Belgian registry of breast implant-associated anaplastic large cell lymphoma


P31 HLTV-1 associated adult T cell leukaemia-lymphoma (ATLL) presenting as cutaneous lymphoma: a case report


P30 The identification of actionable genetic events driving disease progression and heterogeneity in peripheral T cell lymphoma, not otherwise specified


P29 Unravelling the molecular landscape of post-transplant diffuse large B cell lymphoma


P28 Occurrence of high grade B-cell lymphoma with rearrangement of MYC and BCL2 and/or BCL6 under ruxolitinib: a case report


P27 PCLO is overexpressed in ETV6-RUNX1-positive B-cell precursor acute lymphoblastic leukaemia


P26 Long-term follow-up of 2 patients treated with Y-rituximab radioimmunotherapy for relapse of predominantly lymphocytic nodular hodgkin’s lymphoma


P25 Comparison of Multigam® IV (5% 10%) in haematological patients with a secondary immunodeficiency to evaluate infusion time, tolerability and satisfaction. A monocentric observational Belgian study


X